标题
Docetaxel-based combination therapy for castration-resistant prostate cancer
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 21, Issue 11, Pages 2135-2144
出版商
Oxford University Press (OUP)
发表日期
2010-03-30
DOI
10.1093/annonc/mdq050
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
- (2009) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
- (2009) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Phase II study of sunitinib in men with advanced prostate cancer
- (2009) M. Dror Michaelson et al. ANNALS OF ONCOLOGY
- Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
- (2009) Jeanny B. Aragon-Ching et al. BJU INTERNATIONAL
- Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
- (2009) T Koreckij et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer
- (2009) József Horti et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
- (2009) G. Liu et al. CLINICAL CANCER RESEARCH
- Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer
- (2009) Akihiro Matsumoto et al. INTERNATIONAL JOURNAL OF UROLOGY
- Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer
- (2009) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Reply to L.-T. Chen et al
- (2009) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib in Hepatocellular Carcinoma: Redefining Appropriate Dosing, Schedule, and Activity End Points
- (2009) Sandrine J. Faivre et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer
- (2009) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer
- (2009) Ulka N. Vaishampayan et al. JOURNAL OF UROLOGY
- Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial
- (2009) Karim Fizazi et al. JOURNAL OF UROLOGY
- Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer
- (2008) C. N. Sternberg ANNALS OF ONCOLOGY
- Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial
- (2008) Orazio Caffo et al. BJU INTERNATIONAL
- Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
- (2008) Richard D. Sowery et al. BJU INTERNATIONAL
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts
- (2008) Albana Cumashi et al. CANCER LETTERS
- Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
- (2008) S. I. Park et al. CANCER RESEARCH
- A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
- (2008) W. L. Dahut et al. CLINICAL CANCER RESEARCH
- A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer
- (2008) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- A Phase II Study of Estramustine, Docetaxel, and Exisulind in Patients with Hormone- Refractory Prostate Cancer: Results of Cancer and Leukemia Group B Trial 90004
- (2008) Nancy A. Dawson et al. Clinical Genitourinary Cancer
- When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
- (2008) P. Hamberg et al. EUROPEAN JOURNAL OF CANCER
- Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
- (2008) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
- (2008) Nicholas D. James et al. EUROPEAN UROLOGY
- Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
- (2008) Jean-Pascal Machiels et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis
- (2008) K Vandyke et al. LEUKEMIA
- Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyond
- (2008) Matthew R. Smith UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II study
- (2008) Mohammad Reza Safarinejad UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
- (2007) Robert W. Ross et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started